Vaccine Development

GeneThera Purivax technology may facilitate faster development of avian influenza vaccine

Published in Vaccine Weekly, May 3rd, 2006

GeneThera (GTHA) announced that its Purivax technology - a large-scale process for highly purified and high viral titer adenovirus and AAV recombinant vectors, would enable fast track development of adenovirus and AAV-based recombinant DNA vaccines for diseases such as the avian flu (commonly called bird flu).

GeneThera's Purivax, is a multi-resin anion exchange chromatography system that dramatically improves biological purity and viral titer of recombinant adenovirus and AAV vectors. Purivax, completely eliminates toxic side effects associated with adenoviruses and AAV vectors thereby making it possible to quickly develop highly immunogenic and safe recombinant DNA...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2006-05-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry